NCT04106167 - Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions

Advanced Solid TumorLymphomaGastric CancerColorectal CancerHead and Neck CancerSquamous Cell CarcinomaEGFR Positive Solid TumorHER2-positive Breast CancerHepatocellular CarcinomaSmall-cell Lung CancerRenal Cell CarcinomaPancreas CancerMelanomaNSCLCUrothelial CarcinomaCervical CancerMicrosatellite InstabilityMerkel Cell Carcinoma

Interventions

GENETIC

Allogeneic natural killer (NK) cell

No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy

Trial Locations (4)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

77030

MD Anderson Cancer Center, Houston

92093

UCSD Moores Cancer Center, San Diego

07601

Hackensack University Medical Center, Hackensack